Vir Biotechnology Inc (VIR)
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker VIR. The company focuses on discovering and developing therapies aimed at preventing and treating serious infectious diseases in the United States and abroad. Its clinical pipeline includes investigational programs for hepatitis delta virus and certain solid tumors, while its preclinical work covers areas such as influenza A and B antibodies, antibody-drug conjugates, coronavirus monoclonal antibodies, and PRO-XTEN dual-masked T-cell engagers for solid tumors. Vir Biotechnology also maintains multiple research, collaboration, and license agreements with partners including Astellas, Norgine, the Gates Foundation, Brii Biosciences, Alnylam Pharmaceuticals, the Institute for Research in Biomedicine, The Rockefeller University, Xencor, and GlaxoSmithKline Biologicals. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VIR
|
$8.46
|
-10.7% Downside
|
Fair
|
$21.56
|
127.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-3.6x
|
2.0x
|
24.4x
|
1.557 B
|
886.8 M
|
5.8%
|
76.3%
|
1.6
|
—
|
101.6%
|
